Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo - Wikidata - awgldk - TriplyDB

Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo

Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo

http://www.wikidata.org/entity/Q36246828

about

Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression Real-time motion analysis reveals cell directionality as an indicator of breast cancer progression Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding Constraint Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice.Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).2D binary QSAR modeling of LPA3 receptor antagonism.Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.LPA receptor signaling: pharmacology, physiology, and pathophysiology.NFAT proteins: emerging roles in cancer progression.Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis Aiming drug discovery at lysophosphatidic acid targets.Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin Lysophosphatidic acid mediates fibrosis in injured joints by regulating collagen type I biosynthesis.c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme Insights into the pharmacological relevance of lysophospholipid receptors.Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation.An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.Hyaluronic acid hydrogels for biomedical applications.Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine.Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.

P2860

Q24616764-D70D6305-376A-432E-B0B5-08736B38DA23 Q27334635-3549BA35-29C9-4CB2-ACE0-914667CDD55E Q27676584-79FEA941-B3F9-45BF-986B-68551957B69A Q28078129-90096E6F-8D20-4A57-B8BF-DC8454B85E9C Q28260852-9D2FD888-AD50-4953-859C-9667F926FCB3 Q28534911-4C7B34C2-7A37-486E-B8C3-9347EEC13281 Q28538027-F04595D4-4FBE-47BF-8A6A-0E090CE1CB8B Q28550987-45344492-24A3-467B-94E1-467EF48FEAE2 Q30410474-A20DCCBB-4949-4E89-95E9-C55B0315103B Q30410634-63C089A1-4CBE-4289-BA2C-E8AAA4FFDA2F Q30429428-0FF970C0-7B92-48E1-BA3E-EBD000CD6B4B Q33548210-6222D0B3-2960-4716-9B69-278602D73617 Q33759458-C52A5F77-A518-494D-A8CC-EC0CA464DADA Q33825153-59234473-CCA8-4B3C-88E8-7AB4FF924E6B Q33837647-5A02F5F4-4995-4BB0-B409-EA8E29A1F761 Q34145860-8633062B-D8CF-43EE-844B-15A5FBB869B4 Q34339759-F656B5AC-A8D8-4A43-9EA9-94204D3EB65C Q34660049-07C8044B-A4AA-4BF5-8ACC-9C05E146467E Q34874275-FB26F6DF-C032-4EF1-834D-2B2F17787B2E Q35053132-10D21C4C-97D6-4FF4-9C3B-95E989DF472F Q35118841-E927A677-28CE-4DB2-87E0-2B4D111AE18E Q35736010-3C303F80-7D6C-4F90-AB01-49B7508077BD Q35756057-F7CEEDE7-355E-4887-859D-AC4B947367D3 Q35770218-5C9EA4AD-0415-46C0-84F6-A42CB457EFE5 Q35853199-49C46645-AA30-448B-96F4-5F24A4692E03 Q36011319-2F0C6AE3-5D40-4F20-A962-F47EB0E5AB9B Q36299766-5BD22C35-057A-40C0-A93E-470CFD2F2AC2 Q36431033-C554FE13-746E-4D69-8AE8-891AD92289BA Q36452780-883B3D36-8CAD-4DF2-ABCA-467592CDEAD6 Q36664243-E89856CE-023E-4D23-B0CB-C5BB4A72BF39 Q36727390-727C39B9-B966-41D4-8E38-71C9B956D023 Q36863295-F778E3DF-7707-4803-B2B9-330279566800 Q36994700-8E5BB401-62D2-4A83-AD4A-B84707BFCECB Q37003428-7E53C5BC-0406-44BC-B9E0-B642BFE29B1C Q37063026-2A8967A6-1D5E-4AC0-BBE2-64C0D181E6BC Q37177631-7B2074FC-419F-4B4B-ACBA-87488B941A79 Q37367844-0D03A4E4-29EB-45D5-8612-E4253EC00971 Q37372468-D78FC5E3-9A62-4904-89F1-A604376FFA84 Q37868075-50C7BDD6-73E4-4E26-9635-8005F2FAF845 Q38101074-875410B5-4D75-4B92-A292-E785CF861D9B

P2860

Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo

http://www.wikidata.org/entity/Q36246828

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@ast

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@en

type

label

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@ast

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@en

prefLabel

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@ast

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@en

P1433

Q36246828-22C1D476-5D72-48B8-B70E-85677A1D9342

P1476

Q36246828-6A918743-3C48-4F34-8200-983D71569C88

P2093

Q36246828-3A4BFFE1-E352-488C-AEE5-4F9184D1F6EA

Q36246828-4EB9809B-1A84-4677-9F1C-B6D5000E5A90

Q36246828-6497B236-DFD7-4C08-AD9D-26AAECF9AC81

Q36246828-66317675-333C-4B1E-97D4-E0DE84399529

Q36246828-6E684910-7380-4BC6-8960-6DC4207DE7B5

Q36246828-7FF0C863-B96C-4180-A723-C4E7C885C83C

Q36246828-9F2E2177-D8EB-4EA4-BAE8-82EE6295CA5E

Q36246828-C778AAFA-2517-4047-BCFC-D1F937CE73F4

Q36246828-E458AA14-D834-4F67-8F69-7FA6FDCF4985

Q36246828-F0C9668F-9427-4AA5-8C25-862B53EC55C2

P2860

Q36246828-03F428DB-52AB-4B2C-AD89-913A50F69EF8

Q36246828-16FD1D35-8B42-47B5-9C43-B69490FA166A

Q36246828-2C37BF37-405D-4BA9-8058-DA9B8453C535

Q36246828-2D9EAED0-2726-4352-974F-627D2BCA7BD8

Q36246828-308E2654-8BD5-414A-894C-9CBA46E4E161

Q36246828-3246E82D-0F87-43B2-9293-CFE39E33AA8A

Q36246828-36556867-EDFF-494B-A049-A092F1B6031D

Q36246828-3F0B8119-D0E6-4E10-ACAB-45D64C773919

Q36246828-48F889DC-F744-4147-A96C-458B4FE4DF63

Q36246828-5A1C6A34-736C-4AC8-A500-8C85F2DCAD4D

P304

Q36246828-E7ADD635-56E9-4294-94C4-B1739D26F42A

P31

Q36246828-A4069B74-5C8C-48ED-B4F8-F255D95D28DC

P356

Q36246828-341F45CE-A05B-4063-A31D-4A6D6D6643AE

P407

Q36246828-7F429074-0314-495A-B09C-52CC0FEB1BCB

P433

Q36246828-DEC04E2E-3C4B-4E72-8868-E75FB959A15A

P478

Q36246828-67E4101F-2AEC-47E7-9E89-431CD42E6E92

P577

Q36246828-D6F40B43-09F6-4E06-BF2A-384B41744D15

P698

Q36246828-2DA3EAE0-B0C6-48D4-9C76-1532753AD81A

P932

Q36246828-27A4EA1D-C379-4622-B9B6-0B8BD9CE25A8

P356

0008-5472.CAN-09-0302

P1433

Cancer Research

P1476

Dual activity lysophosphatidic ...... auses tumor regression in vivo

@en

P2093

Abby L Parrill

http://www.w3.org/2001/XMLSchema#string

Donna Perygin

http://www.w3.org/2001/XMLSchema#string

Gabor Tigyi

http://www.w3.org/2001/XMLSchema#string

Glenn D Prestwich

http://www.w3.org/2001/XMLSchema#string

Honglu Zhang

http://www.w3.org/2001/XMLSchema#string

James I Fells

http://www.w3.org/2001/XMLSchema#string

Jianxiong Liu

http://www.w3.org/2001/XMLSchema#string

Joanna Gajewiak

http://www.w3.org/2001/XMLSchema#string

Ryoko Tsukahara

http://www.w3.org/2001/XMLSchema#string

Xiaoyu Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Lysophosphatidic acid receptors

The emerging role of lysophosphatidic acid in cancer

Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family

Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor

Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate

GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.

Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

P304

5441-5449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-0302

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19509223

http://www.w3.org/2001/XMLSchema#string

P932

3446773

http://www.w3.org/2001/XMLSchema#string